

Vasocil

Cilostazol

Composition

Vasocil-50: Each tablet contains Cilostazol USP 50 mg.

Vasocil -100: Each tablet contains Cilostazol USP 100 mg.

Description

Vasocil (Cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). Vasocil (Cilostazol) and several of its metabolites are phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively.

Indications

Vasocil (Cilostazol) is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

Dosage and Administration

The recommended dosage of Vasocil (Cilostazol) is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during co administration of such inhibitors of CYP3A4 (eg. ketoconazole, itraconazole, erythromycin and diltiazem) and during co administration of such inhibitors of CYP2C19 as Omeprazole. Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.

Contraindications

Vasocil (Cilostazol) is contraindicated in patients with congestive heart failure of any severity. Vasocil (Cilostazol) is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. Vasocil (Cilostazol) tablets are contraindicated in patients with known or suspected hypersensitivity to any of its components.

Precautions

Vasocil (Cilostazol) should be used with caution in patients with any degree of heart failure. Special caution is advised when Vasocil (Cilostazol) is used in patients with hepatic impairment. Special caution is advised when Vasocil (Cilostazol) is used in patients with severe renal impairment.

Side-effects

Vasocil (Cilostazol) is well tolerated with some most common side effects such as headache, vomiting, rash etc. A few less frequent side effects also been reported such as anorexia, face oedema etc.

Use in Pregnancy and Lactation

Pregnancy

There are no adequate and well controlled studies in pregnant women, so use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation

As Vasocil (Cilostazol) is secreted into the milk of experimental animals, there is potential risk for the nursing infants, so a decision should be made to discontinue nursing or to discontinue Vasocil (Cilostazol).

Drug Interactions

Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of Cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of Cilostazol among patients concurrently treated with diltiazem. There is limited information with respect to the efficacy or safety of the concurrent use of Cilostazol and clopidogrel.

Over dosage

Information on acute overdosage with Vasocil (Cilostazol) in humans is limited. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmia. The patient should be carefully observed and given supportive treatment.

Presentation

Vasocil -50: Each box contains 3 X 10 tablets in Alu-Alu blister strips.

Vasocil -100: Each box contains 2 X 10 tablets in Alu-Alu blister strips

Manufactured by:



The IBN SINA Pharmaceutical Industry Ltd.
Shafipur, Gazipur, Bangladesh.